mRNA-1195 / Moderna - LARVOL DELTA

A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years (clinicaltrials.gov) - P2 | N=180 | Recruiting | Sponsor: ModernaTX, Inc. | Not yet recruiting ➔ Recruiting

Enrollment open • CNS Disorders • Multiple Sclerosis

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Participants (clinicaltrials.gov) - P1 | N=474 | Recruiting | Sponsor: ModernaTX, Inc. | Active, not recruiting ➔ Recruiting | N=354 ➔ 474

Enrollment change • Enrollment open • Epstein-Barr Virus Infections • Infectious Disease

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Adults (clinicaltrials.gov) - P1 | N=354 | Active, not recruiting | Sponsor: ModernaTX, Inc. | Trial completion date: Feb 2026 ➔ Jun 2027 | Trial primary completion date: Feb 2026 ➔ Jun 2027

Trial completion date • Trial primary completion date • Epstein-Barr Virus Infections • Infectious Disease

A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years (clinicaltrials.gov) - P2 | N=180 | Not yet recruiting | Sponsor: ModernaTX, Inc. | Initiation date: Dec 2024 ➔ Apr 2025

Trial initiation date • CNS Disorders • Multiple Sclerosis

A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years (clinicaltrials.gov) - P2 | N=180 | Not yet recruiting | Sponsor: ModernaTX, Inc.

New P2 trial • CNS Disorders • Multiple Sclerosis

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Adults (clinicaltrials.gov) - P1 | N=354 | Active, not recruiting | Sponsor: ModernaTX, Inc. | Recruiting ➔ Active, not recruiting

Enrollment closed • Epstein-Barr Virus Infections • Infectious Disease

A Study of an Epstein-Barr Virus (EBV) Candidate Vaccine, mRNA-1195, in 18- to 55-Year-Old Healthy Adults (clinicaltrials.gov) - P1 | N=500 | Recruiting | Sponsor: ModernaTX, Inc.

New P1 trial • Epstein-Barr Virus Infections • Infectious Disease